Forrest Glover, MD
Cardiovascular Disease · Little Rock, ARNPI 1548440522
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $13,735 of the $16,580 with a category attached, or 82.8%. It is spread thinly across 20 manufacturers, the largest accounting for just 23.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $4,038 and has fallen 59.7% since, to $1,629 in 2025.
Across 406 payments — averaging $40.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$4K
- Edwards Lifesciences$3K
- Abiomed$3K
- Abbott$3K
- Boston Scientific$2K
- Cardiovascular Systems Inc.$436
- plus $1K from 14 others
What the payments were for
- Speaking & faculty fees$2,81317%
- Travel & lodging$320%
- Food & beverage$13,73583%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 28 | $3,833 |
| Edwards Lifesciences | 78 | $3,062 |
| Abiomed | 70 | $2,880 |
| Abbott | 86 | $2,761 |
| Boston Scientific | 56 | $2,213 |
| Cardiovascular Systems Inc. | 10 | $436 |
| Novartis | 34 | $415 |
| Shockwave Medical, Inc | 4 | $255 |
| Johnson & Johnson | 13 | $182 |
| Boehringer Ingelheim | 1 | $115 |
| E.r. Squibb & Sons, L.L.C. | 6 | $100 |
| AstraZeneca | 5 | $75 |
| Lantheus Medical Imaging, Inc. | 3 | $54 |
| Lexicon Pharmaceuticals, Inc. | 3 | $53 |
| Pfizer | 4 | $48 |
| Biosense Webster, Inc. | 1 | $34 |
| Inari Medical, Inc. | 1 | $18 |
| Merck | 1 | $15 |
| Bridgebio Pharma, Inc. | 1 | $15 |
| Teleflex LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CoreValve Evolut$2,914
- Impella$1,078
- Edwards SAPIEN 3 Transcatheter Heart Valve$539
- COREVALVE EVOLUT R$333
- MitraClip$329
- Mitra Clip system$242
- GENERAL - STRUCTURAL HEART$211
- PASCAL$173
- NAVITOR$143
- MitraClip System$124
- Peripheral Orbital Atherectomy System$121
- Coronary Orbital Atherectomy System$121
- GENERAL - THERAPIES$117
- JARDIANCE$115
- AMPLATZER AMULET$113
- Sentinel$105
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$103
How this compares
$16,580 in reported general payments places this provider in the 85th percentile of 130 cardiovascular disease providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 322 | $240,932 |
| CamzyosMavacamten | 12 | $91,554 |
| EntrestoSacubitril/Valsartan | 63 | $61,229 |
| XareltoRivaroxaban | 69 | $44,754 |
| Repatha SureclickEvolocumab | 47 | $27,110 |
| Praluent PenAlirocumab | 16 | $19,504 |
| BrilintaTicagrelor | 32 | $18,094 |
| FarxigaDapagliflozin Propanediol | 27 | $16,951 |
| Ranolazine ErRanolazine | 74 | $4,720 |
| Atorvastatin Calcium | 406 | $3,320 |
| Carvedilol | 314 | $2,601 |
| Losartan Potassium | 246 | $1,939 |
| Nebivolol Hcl | 24 | $1,831 |
| Metoprolol Succinate | 136 | $1,611 |
| ClopidogrelClopidogrel Bisulfate | 182 | $1,421 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $48 | $240,932322 claims |
| E.r. Squibb & Sons, L.L.C.Camzyos | $100 | $91,55412 claims |
| NovartisEntresto | $415 | $61,22963 claims |
| Johnson & JohnsonXarelto | $182 | $44,75469 claims |
| AstraZenecaBrilinta, Farxiga | $75 | $35,04459 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 130 cardiovascular disease providers in Arkansas.
Other cardiovascular disease in Little Rock
- Ian CawichLittle Rock$294K
- William RollefsonLittle Rock$74K
- Andre PaixaoLittle Rock$73K
- Wesley LaneLittle Rock$46K
- Omar QaqishLittle Rock$45K
- Barry UretskyLittle Rock$36K
- Freddy ChrismanLittle Rock$26K
- Clayton BorgLittle Rock$14K
- David MegoLittle Rock$14K
- Michael HuberLittle Rock$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.